News | July 13, 2012

GE, VPDiagnostics Collaborate on MRI of Carotid Artery Atherosclerosis Imaging, Plaque Analysis

New collaboration aims to improve research and clinical development in vulnerable plaque assessment

MRI-PlaqueView's 3-D visualization of carotid plaque morphology and composition.

July 13, 2012 — GE Healthcare and VPDiagnostics Inc. jointly announced today their co-marketing agreement for the VPDiagnostics’ MRI-PlaqueView software for carotid artery atherosclerosis analysis. The MRI-PlaqueView software is compatible with carotid magnetic resonance imaging (MRI) data acquired from GE 3.0T MRI systems (HDxt and Discovery MR750). The collaboration will aim to develop optimized carotid imaging protocols and future co-developments on new techniques.

Carotid atherosclerosis may be responsible for as much as one-third of all strokes. To better gauge risk of stroke from carotid atherosclerosis, clinicians are beginning to look beyond traditional risk factors such as carotid artery narrowing (stenosis) to identify high-risk features of the atherosclerotic plaque itself. The GE 3.0T MRI systems and dedicated carotid coil enables high-resolution multi-contrast imaging of carotid lumens, vessel walls and atherosclerotic plaques, while the MRI PlaqueView software from VPDiagnostics provides analysis of these images to delineate various plaque components such as vessel wall, calcified and soft plaques, and help provide a better assessment of the plaque characteristics.

For more information: 


Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init